PYRILUTAMIDE 0.5% Spray Bottle for Easy Application on Scalp - (EU Shipping)

Product Information

In December 2022, the results of another phase-2 clinical study were published, on the treatment of female pattern hair loss (female AGA).

Pyrilutamide KX-826 | Ligand Chem, UK, Europe, America

Pyrilutamide (KX-826) is a topical androgen receptor (AR) antagonist, being developed as a potential topical treatment for androgenetic alopecia. Results showed that the pyrilutamide 0.5% solution applied once daily significantly increased the hair count by 11.39 hairs per cm 2 from baseline after 24 weeks of treatment. Improvement in hair density was seen as early by the end of week 12. Like the previous phase II trials, it exhibited a good safety profile. Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high- affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of androgenic alopecia (androgen-dependent scalp hair loss) [1] and acne in China and the United States. [2] [3] As of October 2022, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne. [2] Development [ edit ] It does seem like it's so far proving very effective in terms of the clinical trial data for hair loss and i do think for a lot of guys it will be interesting to see if it could possibly replace both Finasteride and Minoxodil as a combination treatment to just relying on a single treatment for those suffering hair loss in the early stages.

Get updates

The primary endpoint is the change from baseline in non- vellus target area hair count (TAHC) at the end of week 24. The drug will be dosed at 10 mg (0.5% BID) per patient per day in the trial. [4] Adverse effects [ edit ] Pyrilutamide (also known as KX-826) is a high potency antagonist of the androgen receptor, and is currently the strongest available topical anti-androgen. It is in stage II clinical trials in the US for treatment of androgenic alopecia, and stage III trials in China for the same condition.

What Is Pyrilutamide (KX-826)? - HairScience

It's a game changer imo because as somebody above mentioned, people that can't tolerate Finasteride/Dutasteride orally or topically because of sides no longer have to worry about that issue and still have the ability to save their hair. The attributes with substantial impact on PTSR and LoA have the maximum weightage in the model, while the less impactful attributes have intermediate or low weightage. The blood concentration of pyrilutamide among the subjects remained extremely low throughout the study. In terms of safety, there were no associated severe adverse drug events. Phase-2 clinical trialsA recently completed phase-1 clinical trial done in the US was a randomized, double-blind, placebo-controlled, parallel-group, and dose-escalation study. It involved 40 healthy adult male patients with androgenetic alopecia.